Compare TNXP & MFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TNXP | MFM |
|---|---|---|
| Founded | 2007 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 224.5M |
| IPO Year | 2008 | N/A |
| Metric | TNXP | MFM |
|---|---|---|
| Price | $9.26 | $4.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $44.50 | N/A |
| AVG Volume (30 Days) | 374.3K | ★ 471.9K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.08% |
| EPS Growth | ★ 91.75 | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $319.65 | N/A |
| Revenue Next Year | $101.60 | N/A |
| P/E Ratio | ★ N/A | $162.67 |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $9.40 | $4.76 |
| 52 Week High | $24.64 | $5.67 |
| Indicator | TNXP | MFM |
|---|---|---|
| Relative Strength Index (RSI) | 26.70 | 24.64 |
| Support Level | $9.40 | N/A |
| Resistance Level | $12.99 | $5.63 |
| Average True Range (ATR) | 0.50 | 0.08 |
| MACD | -0.18 | -0.02 |
| Stochastic Oscillator | 3.73 | 25.58 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.